The goal of this clinical research study is to find the highest tolerable dose of azacitidine
that can be given with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell
transplant, and with or without rituximab. Researchers also want to learn about the safety
and level of effectiveness of this combination.